65,437 trials
Perioperative Inflammatory Response
Primary: Median Concentration of Aspartate Aminotransferase (AST) — 24.5; 24.5; 21.0; 20.0 U/L
Asthma
Primary: Change in Mean Methacholine Responsiveness as Assessed by the Provocation Concentration Causing a 20% Fall in Forced Expiratory Volume in One Second (FEV1) (PC20) at…
Autistic Disorder
Primary: Total Number of Subjects With Reported Side Effects as Assessed by Dosage Record and Treatment Emergent Symptom Scale (DOTES) — 11; 7; 3; 2 participants
Ulcerative Colitis
Primary: Percentage of Participants In Remission at Week 52 — 34.3; 40.6; 11.1 percentage of participants — p=<0.0001
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Change From Baseline in Mean Systolic Blood Pressure at Final Assessment — 107.5; 113.5; 0.9; 0.3 millimeter of mercury (mmHg)
Giant Cell Arteritis
Primary: Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper) — 56.0; 53.1; 14.0…
Refractory Plasma Cell Myeloma
Primary: Number of Patients Surviving Progression-free — 14 Participants
Non-Hodgkin Lymphoma · Chronic Lymphocytic Leukemia
Primary: Number of Patients With an Objective Response — 4 Participants
Chronic Pain
Primary: Visual Analog Scale (VAS) Pain Diary Scores for Average Overall Pain — 43.5; 48.7 mm — p=<0.001
Iris Melanoma · Medium/Large Size Posterior Uveal Melanoma · Ocular Melanoma With Extraocular Extension
Primary: Progression-free Survival (PFS) (Evaluable Randomized Patients) — 7; 15.9 weeks
Acute Ischemic Stroke
Primary: 90-day Global Disability Assessed Via the Blinded Evaluation of Modified Rankin Score (mRS). — 17; 8; 25; 10 Participants
Atopic Dermatitis
Primary: Investigator Global Assessment of Improvement — 2; 2; 2 units on a scale
Circulatory; Change
Primary: Peak Systolic Velocities (PSV) Measurement by Renal Doppler Ultrasound (US) Examination Evaluating the Effects of Flexible Ureteroscopy (F-URS) on Renal Blood Flow by…
Food Hypersensitivity
Primary: Percentage of Subjects Who Can Tolerate the Peanut Oral Food Challenge After 12 Months of Peanut SLIT Dosing — 45.5; 0; 11.8; 66.7 percentage of participants
Cocaine Dependence
Primary: Abstinence (Weeks 10 - 11) — 4; 7 Participants